ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Subscribe To Our Newsletter & Stay Updated